Research
My research interests are in industrial, health and public economics. Most of the research I have performed in the first two fields concerns the pharmaceutical market.
Current research projects:
Price effects of competition from parallel imports and therapeutic alternatives for patent protected pharmaceuticals [Priseffekter av konkurrens från parallellimport och terapeutiska alternativ för patentskyddade läkemedel] Financed by the Swedish Competition Authority [Konkurrensverket]. Oct. 2018- Sept. 2020. Project leader: David Granlund.
Within- and across-consumer learning and structural state dependence. Financed by the Jan Wallander and Tom Hedelius Foundation and the Tore Browaldhs Foundation. July 2016-June 2019. Project leader: David Granlund. Co-applicants Andrew Ching, University of Toronto and David Sundström, Umeå University.
I am a member of The Economic Policy Network.
Articles in international scientific journals
Price competition in pharmaceuticals – evidence from 1303 Swedish markets, with M A Bergman, Journal of Health Economics 61, 1-12. Results from three extensions
Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals, with M Bergman and N Rudholm, Oxford Bulletin of Economics and Statistics 79(6), 969-996.
Free view-only version
Federal Subsidization of State Expenditure to Reduce Political Budget Cycles, with T Aronsson, International Tax and Public Finance 24(3), 536-545, 2017.
Free view-only version
Post-refereeing-version
Reforming the Swedish pharmaceuticals market: Consequences for costs per defined daily dose, with M Bergman and N Rudholm. International Journal of Health Economics and Management, 16(3), 201-214, 2016.
Free view-only version
Post-refereeing-version
EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals: Has the Price Competition increased? With M Y Köksal-Ayhan. The B.E. Journal of Economic Analysis and Policy 16(2), 1069–1092, 2016.
Published version
The effect of pharmacies' right to negotiate discounts on the market share of parallel imported pharmaceuticals. The B.E. Journal of Economic Analysis and Policy 15, 1197-1235, 2015.
Published version
Parallel Imports and Mandatory Substitution Reform – A Kick or A Muff for Price Competition? The European Journal of Health Economics, 16(9), 969-983, 2015 (with M Koksal-Ayhan)
Free view-only version
Post-refereeing-version
Introducing waiting times for health care in a labor supply model for sickness absence, with D Andrén, Nordic Journal of Health Economics 3, 34-46, 2014 (Open Access)
WP-version
Present-Biased Preferences and Publicly Provided Private Goods. FinanzArchiv/Public Finance Analysis 70(2), 169-199, 2014. (with T Aronsson)
Post-refereeing-version
WP-version
The prescribing physician's influence on consumer choice between medically equivalent pharmaceuticals. Review of Industrial Organization 41, 207-222, 2012. (with N Rudholm) (The final publication is available at springerlink.com.)
Free view-only version
Post-refereeing-version
Electoral accountability in a country with two-tiered government, Public Choice 148, 531-546, 2011. (The final publication is avialable at www.springerlink.com.)
Free view-only version
Post-refereeing-version
Public goods and optimal paternalism under present-biased preferences, Economics Letters 113, 54-57, 2011 (with T Aronsson).
Post-refereeing-version
Price and welfare effects of a pharmaceutical substitution reform, Journal of Health Economics 29, 856-865, 2010.
Post-refereeing-version
Consumer information and pharmaceutical prices: Theory and Evidence, Oxford bulletin of Economics and Statistics 73(2), 230-254, 2011. (with N Rudholm)
Free view-only version
WP-version
Additional results
The effect of health care expenditure on sickness absence, The European Journal of Health Economics 11, 555-568, 2010 (The final publication available at www.springerlink.com.)
Free view-only version
Post-refereeing-version
Inequality in mortality in Vietnam during a period of rapid transition, Social Science & Medicine 70, 232-239, 2010. (with N T Chuc, H D Phuc and L Lindholm, the final publication)
Post-refereeing-version
Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? Social Science & Medicine 69, 1643-1650, 2009. (The final publication).
Post-refereeing-version
Additional results
Sickness absence and health care in an economic federation, International Tax and Public Finance 14, 503-524, 2007 (The final publication).
Free view-only version
Post-refereeing-version
Fixed budgets as a cost containment measure for pharmaceuticals, The European Journal of Health Economics 7, 37-45, 2006. (with N Rudholm and M Wikström, the final publication available at www.springerlink.com.)
Free view-only version
WP-version
Thesis:
Economic policy in health care – sickness absence and pharmaceutical costs
